This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 1-7 June 2024 and includes updates on SARS-CoV-2 variant classification, cholera, out-of-season increase in norovirus, seasonal surveillance on West Nile virus infections, Middle East respiratory syndrome coronavirus (MERS-CoV), influenza A(H5N2), Oropouche virus disease, and an overview of respiratory virus epidemiology in the EU/EEA.
The ECDC updates are based on available data reported through the European Surveillance System (TESSy) by the national public health authorities of EU/EEA countries.
Due to the concerning rise in sexually transmitted infection (STIs) transmission across Europe, the European Centre for Disease Prevention and Control (ECDC) is urging everyone to keep informed and practice safer sex as they leave for holidays, festivals, and travel this summer season.
This framework describes the building blocks and actions that ECDC will use to support and EU/EEA countries and the European Commission to achieve the Sustainable Development Goal (SDG).
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
This issue of the ECDC Communicable Disease Threats Report (CDTR) covers the period 21–27 April 2024 and includes updates on respiratory virus epidemiology in the EU/EEA, West Nile virus, SARS-CoV-2 variant classification and Cholera.
Influenza, SARS-CoV-2 and RSV activity in EU/EEA Member States continue to decrease or remain stable at low levels. Cases, including severe infections, can still occur and it therefore remains essential to continue testing patients presenting with severe acute respiratory symptoms in order to guide treatment and inform epidemiological assessments.
The decline in the reported number of new transmissions of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections across European Union (EU) and European Economic Area (EEA) countries has continued.